Lymphoma, Follicular
Conditions
Brief summary
A previous phase II trial entitled Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon was conducted at the Odette Cancer Centre between 2005 and 2012. The primary objectives of this previous trial was to assess progression free survival and overall survival. Of the 36 patients in this trial, approximately 18 remain in remission. In this new follow up trial, follow up data will prospectively be collected on patients who provide informed consent to do so.
Interventions
OTHERFollow up
Sponsors
Sunnybrook Health Sciences Centre
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with 1-2 relapses of WHO Classification follicle centre NHL grade 1-2/3. Patients must have achieved at least a PR to previous treatment. * Central pathology review before registration * Ann Arbor stage III or IV * Measurable disease: defined as clinically or radiologically documented disease with at least one site bidimensionally measurable using clinical exam, CT or MRI performed in the 3 weeks prior to study enrollment. * ECOG performance status of \<2. * Patients may have received not more than 1 prior course (4 infusions) of rituximab. Timing from last dose of rituximab must exceed 6 months prior to registration. Patients must have demonstrated at least a PR to rituximab if previously administered. * Patient consent according to institutional and university human experimentation committee requirements * Adequate Renal, hepatic and hematopoietic function test unless the abnormal values are thought to be due to involvement with lymphoma as defined by: * Hb\> 85 * ANC \>1000/mm3 * Platelets \>100,000/mm3 * Serum/Total Bilirubin \>=2 SI units * AST/ALT \<2x Upper Limit of Normal
Exclusion criteria
* Positive serology for HIV * Uncontrolled Infection * Pregnancy * CNS Metastases * History of Psychiatric Disorder * Other Malignancy (except nonmelanoma skin cancer) * Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions, which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives. * Major surgery, other than diagnostic surgery, within four weeks. * Presence of anti-murine antibody (HAMA) reactivity. These laboratory results must be available prior to receiving treatment for those patients * who have received prior murine proteins or patients who have allergies to murine proteins. * New York Heart Association Class III or IV heart disease (see Appendix H, Clinical Evaluation of Functional Capacity of Patients with Heart Disease in Relation to Ordinary Physical Activity) or myocardial infarction within the past six months. * Treatment with an investigational drug within 30 days or five half-lives (of the study drug with the longest half-life) prior to entry into the study, which ever is longer. * Previous chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of other malignancy except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix within the last 5 years. * History of allergic reactions to compounds chemically related to Rituximab. * Refusal to practice contraception if of reproductive potential.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | through study completion, up to 15 years | Number of months from date of enrollment to date of death or last follow-up, whichever comes first. |
| Progression-free survival | through study completion, up to 15 years | Number of months from date of enrollment to date of progression. Progression is defined as a greater than or equal to 50% increase in the sum of the product of measurable lesions. Appearance of new lesions will also constitute progressive disease. |
| Event-free survival | through study completion, up to 15 years | Number of months from date of enrollment to date of an event. An event is defined as death, disease progression, transformation, or development of secondary malignancy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events possibly or probably related to transplant | through study completion, up to 15 years | Adverse events include second malignancies, myelodysplastic syndrome (MDS), hypogammaglobulinemia, and pulmonary fibrosis. This outcome measurement is descriptive. |
| Minimal Residual Disease | through study completion, up to 15 years | This exploratory endpoint is used to evaluate the detection of recurrent lymphoma in peripheral blood DNA. It is measured as real-time quantitative polymerase chain reaction (RQ-PCR) and is expressed as a percent of detection per 100,000 cells at each follow-up time point. |
Countries
Canada
Outcome results
None listed